EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19
This work was funded by European League Against Rheumatism (CLI122). PMM is supported by the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (BRC). JDI is a NIHR Senior Investigator and his work is supported by the NIHR Newcastle Bi...
| Autores: | , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2021 |
| País: | España |
| Institución: | Universidad de Oviedo (UNIOVI) |
| Repositorio: | RUO. Repositorio Institucional de la Universidad de Oviedo |
| Idioma: | inglés |
| OAI Identifier: | oai:digibuo.uniovi.es:10651/59324 |
| Acceso en línea: | http://hdl.handle.net/10651/59324 https://dx.doi.org/10.1136/annrheumdis-2020-219724 |
| Access Level: | acceso abierto |
| Sumario: | This work was funded by European League Against Rheumatism (CLI122). PMM is supported by the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (BRC). JDI is a NIHR Senior Investigator and his work is supported by the NIHR Newcastle Biomedical Research Centre in Ageing and Long- Term Conditions, and the Research Into Inflammatory Arthritis Centre versus Arthritis. AVR is a member of the paediatric steering committee of RECOVERY, the steering committee of COVINTOC study and the steering committee of baricitinib in COVID-19. |
|---|